(Effect Of Mirabegron Versus Solifenacin In Treatment Of Over Active Bladder (Prospective Randomized controlled study

Abstract

Overactive bladder (OAB) syndrome is a chronic disease characterized by urinary urgency with or without urge incontinence, frequency and nocturia with huge economic burdens and detrimental effects on the quality of life of patients. The prevalence of OAB in patients increases with age probably due to the functional and structural changes in the bladder, caused by ischemic processes. Antimuscarinic agents represent the mainstay of pharmacotherapy for OAB and several meta analyses have confirmed their efficacy. Despite the presence of side effects and the high percentage of patients discontinuing treatment after a few months, they represent the first-line pharmacological therapy recommended for OAB treatment. Solifenacin succinate is an effective muscarinic receptor antagonist with selectivity for M3 receptor in the urinary bladder. It has shown significant improvement of the symptoms compared with placebo in patients with OAB.